T1	Participants 180 296	Patient preference for benign prostatic hyperplasia (BPH) treatment with the Î±(1)-blockers, tamsulosin or silodosin,
T2	Participants 343 414	Japanese patients with lower urinary tract symptoms associated with BPH
T3	Participants 824 858	102 patients (mean age 70.3 years)
